Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells.  
  
Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor.  PRTH-101 is poised to enter Phase 1 clinical trials.  
 
PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion.  

Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.  

Biotechnology

Health Care

Life Sciences

Pharmaceutical

Incendia Therapeutics

Incendia Therapeutics' headquarters in Boston, United States

The Scientific and Research Team at Incendia Therapeutics spearheads the discovery and development of novel anti-cancer medicines, focusing on reprogramming the tumor microenvironment. This team conducts cutting-edge research to elucidate the interactions among cancer cells, stromal cells, and immune cells, and develops innovative therapies like PRTH-101. They also leverage AI technology for precision oncology, enabling biomarker-driven patient selection to optimize clinical applications.

Scientific and Research Team

The Leadership Team at Incendia Therapeutics is responsible for steering the company's strategic direction, overseeing the development and clinical testing of innovative anti-cancer therapies like PRTH-101, and ensuring the integration of precision oncology approaches. This team, composed of experienced industry leaders and scientific experts, drives critical decision-making processes, manages cross-functional projects, and fosters partnerships to advance the company’s mission of transforming cancer treatment through novel approaches to reprogramming the tumor microenvironment.

Leadership Team

The Research and Development team at Incendia Therapeutics is focused on discovering and developing novel anti-cancer therapies that modulate the tumor microenvironment to overcome immune exclusion barriers. They lead the development of groundbreaking programs, such as the PRTH-101 monoclonal antibody, and manage the pipeline of preclinical projects targeting various aspects of the tumor microenvironment. This team integrates proprietary AI technology and precision oncology to enable biomarker-driven patient selection, ensuring that the right medicines reach the right patients.

Research and Development

The Operations Team at Incendia Therapeutics is responsible for ensuring the seamless execution of the company's drug discovery and development programs. This includes overseeing clinical operations, managing facilities and procurement, coordinating lab operations, and driving strategic development initiatives. Their efforts are crucial in maintaining efficiency and ensuring that projects like PRTH-101 progress smoothly towards clinical trials and beyond, supporting the company’s mission to deliver targeted anti-cancer therapies.

��

People (8)

Jobs (0)

Other teams

Leadership Team

Research and Development

Operations Team

��������

People (8)

Jobs (0)

Other teams

Leadership Team

Research and Development

Operations Team

��